Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02666950 · OUTCOME

Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline

WEE1 Inhibitor AZD1775 With or Without Cytarabine in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome · Source last updated 2019-09-06

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 17 months

What was measured

Clinical benefit as measured by the number of patients who did not receive a RBC transfusion post-Baseline

Analysis population: Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.

Groups in this outcome

Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)

Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)3

Reported measurements

Source class 1
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    units
    Participants
description
Clinical benefit as measured by the number of patients who did not receive a RBC transfusion post-Baseline
groups
  1. description
    Patients receive 20 mg cytarabine (AraC) SC twice daily and 200 mg WEE1 inhibitor (AZD1775) PO daily on days 1-5 and days 8-12 OR receive only 200 mg WEE inhibitor (AZD1775) PO daily on days 1-5, 8-12, 15-19, and 22-26.
    id
    OG000
    title
    Arm A + Arm C (AZD1775 Combined With AraC OR AZD1775 Only)
param Type
COUNT_OF_PARTICIPANTS
population Description
Since only one patient was accrued on one arm, patient confidentiality prevents the reporting of results by arm.
reporting Status
POSTED
time Frame
Up to 17 months
title
Clinical Benefit as Measured by the Number of Patients Who Were Not RBC Transfusion-dependent Post-Baseline
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice